Other clinical trials have tested a drug called Cladribine, a powerful intravenous chemotherapy drug used for leukemia, in Type II refractory patients. One trial, conducted in the Netherlands, found ...

In 2024, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and ...

A number of oral therapies are in a late stage of development for MS (Table 2). In addition to cladribine tablets, for which key data are reviewed below, oral therapies undergoing investigation in ...

Use of the approved therapy Mavenclad (cladribine) — given as a short treatment course, consisting of up to 20 therapy days spanning two years — led to low rates of disability progression ...

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Cladribine is under development for the treatment of neurological ...

Cladribine is rapidly absorbed with maximum concentration reached 30–50 min after oral administration and 0–20% bound to plasma protein. The half-life varies from 5.6 to 7.6 h and 18.4 to 19.7 ...

(“BioNxt” or the “Company”) (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its ...

SAN DIEGO ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible ...

22,24,25 The final oral agent, cladribine, has immune-suppressing effects derived from inhibiting DNA synthesis; it was approved by the FDA in 2019. Due to its safety profile, cladribine is ...